CoChat
Cited by 185

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Open access
Kramvis, Anna, Chang, Kyong-Mi, Dandri, Maura, Farci, Patrizia, Glebe, Dieter, Hu, Jianming, Janssen, Harry L. A., Lau, Daryl T. Y., Penicaud, Capucine, Pollicino, Teresa, Testoni, Barbara, Van Bömmel, Florian, Andrisani, Ourania, Beumont-Mauviel, Maria, Block, Timothy M., Chan, Henry L. Y., Cloherty, Gavin A., Delaney, William E., Geretti, Anna Maria, Gehring, Adam, Jackson, Kathy, Lenz, Oliver, Maini, Mala K., Miller, Veronica, Protzer, Ulrike, Yang, Jenny C., Yuen, Man-Fung, Zoulim, Fabien, Revill, Peter A. · 2022 · Nature Reviews Gastroenterology & Hepatology

Abstract

Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers. Currently, there is no cure for hepatitis B virus (HBV) infection, which can lead to chronic liver disease and liver cancer, and only a few biomarkers are available. This Roadmap provides an overview of HBV serum biomarkers and their challenges. As new therapies for hepatitis B virus (HBV) infection become available, new biomarkers to monitor viral and host responses are urgently needed. This Roadmap summarizes current knowledge on existing and emerging serum biomarkers in the context of chronic HBV infection. This Roadmap discusses the strengths, weaknesses, opportunities and challenges of serum HBV biomarkers. This Roadmap provides suggestions of the way forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage. As new therapies for hepatitis B virus (HBV) infection become available, new biomarkers to monitor viral and host responses are urgently needed. This Roadmap summarizes current knowledge on existing and emerging serum biomarkers in the context of chronic HBV infection. This Roadmap discusses the strengths, weaknesses, opportunities and challenges of serum HBV biomarkers. This Roadmap provides suggestions of the way forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41575-022-00649-z

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 185

Metadata

Authors
Kramvis, A., Chang, K.-M., Dandri, M., Farci, P., Glebe, D., Hu, J., Janssen, H. L. A., Lau, D. T. Y., Penicaud, C., Pollicino, T., Testoni, B., Van Bömmel, F., Andrisani, O., Beumont-Mauviel, M., Block, T. M., Chan, H. L. Y., Cloherty, G. A., Delaney, W. E., Geretti, A. M., Gehring, A., Jackson, K., Lenz, O., Maini, M. K., Miller, V., Protzer, U., Yang, J. C., Yuen, M.-F., Zoulim, F., & Revill, P. A.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2022-07-20
Volume
19
Issue
11
Pages
727-745
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W4286007825
Cited by
185
References
14
FWCI
8.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. https://app.cochat.ai/papers/10.1038/s41575-022-00649-z
The paper
Kramvis, A., Chang, K.-M., Dandri, M., Farci, P., Glebe, D., Hu, J., Janssen, H. L. A., Lau, D. T. Y., Penicaud, C., Pollicino, T., Testoni, B., Van Bömmel, F., Andrisani, O., Beumont-Mauviel, M., Block, T. M., Chan, H. L. Y., Cloherty, G. A., Delaney, W. E., Geretti, A. M., . . . Revill, P. A. (2022). A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-022-00649-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.